BACKGROUND: External acuminata condylomata (EAC) are among the most common sexually transmitted diseases. Although it is understood that low-risk human papillomavirus (HPV) genotypes 6 and 11 are associated with EAC, there have only been a few, small, published studies reporting the genotype-specific prevalence of HPV. The objective of our study was to assess the prevalence of HPV genotypes for a large number of cases involving both men and women and to evaluate the potential benefit of a quadrivalent (genotypes 6, 11, 16, and 18) HPV vaccine in France. METHODS: A total of 256 women and 260 men who presented with EAC to French gynecologists, dermatologists, and proctologists were prospectively recruited during the period January through April 2007. Specimens were collected with a cytobrush, and the HPV genotype was determined using the INNO-LiPA assay (Innogenetics), which detects 24 HPV genotypes. RESULTS: Four hundred twenty-three beta-globin-positive samples could be analyzed. The median age of patients was 30 years (range, 18-72 years). The overall prevalence of HPV DNA in patients with EAC was 99% (33% of patients were coinfected with another pathogen). Low-risk genotypes predominated, with a prevalence of 89%. The most prevalent genotypes were 6 (69%) and 11 (16%), followed by 16 (9%), 51 (8%), 52 (7%), 66 (6%) 53 (5%), 31 (3%), and 18 (3%). The cumulative prevalence of genotypes 6 and 11 was 83%, and the cumulative prevalence of genotypes 6, 11, 16, and 18 was 88%. CONCLUSIONS: This study is, to our knowledge, the first large, multicenter survey to provide solid data on HPV genotype distribution among patients with EAC. Our results provide strong evidence that, in France, the most prevalent HPV genotypes in persons with EAC are 6 and 11. Because of its 99% efficacy for the prevention of EAC and a vaccine coverage of 100%, the quadrivalent HPV vaccine could prevent 62%-87% of EAC cases in France.
BACKGROUND: External acuminata condylomata (EAC) are among the most common sexually transmitted diseases. Although it is understood that low-risk human papillomavirus (HPV) genotypes 6 and 11 are associated with EAC, there have only been a few, small, published studies reporting the genotype-specific prevalence of HPV. The objective of our study was to assess the prevalence of HPV genotypes for a large number of cases involving both men and women and to evaluate the potential benefit of a quadrivalent (genotypes 6, 11, 16, and 18) HPV vaccine in France. METHODS: A total of 256 women and 260 men who presented with EAC to French gynecologists, dermatologists, and proctologists were prospectively recruited during the period January through April 2007. Specimens were collected with a cytobrush, and the HPV genotype was determined using the INNO-LiPA assay (Innogenetics), which detects 24 HPV genotypes. RESULTS: Four hundred twenty-three beta-globin-positive samples could be analyzed. The median age of patients was 30 years (range, 18-72 years). The overall prevalence of HPV DNA in patients with EAC was 99% (33% of patients were coinfected with another pathogen). Low-risk genotypes predominated, with a prevalence of 89%. The most prevalent genotypes were 6 (69%) and 11 (16%), followed by 16 (9%), 51 (8%), 52 (7%), 66 (6%) 53 (5%), 31 (3%), and 18 (3%). The cumulative prevalence of genotypes 6 and 11 was 83%, and the cumulative prevalence of genotypes 6, 11, 16, and 18 was 88%. CONCLUSIONS: This study is, to our knowledge, the first large, multicenter survey to provide solid data on HPV genotype distribution among patients with EAC. Our results provide strong evidence that, in France, the most prevalent HPV genotypes in persons with EAC are 6 and 11. Because of its 99% efficacy for the prevention of EAC and a vaccine coverage of 100%, the quadrivalent HPV vaccine could prevent 62%-87% of EAC cases in France.
Authors: Gabriella M Anic; Ji-Hyun Lee; Luisa L Villa; Eduardo Lazcano-Ponce; Christine Gage; Roberto José C Silva; Maria L Baggio; Manuel Quiterio; Jorge Salmerón; Mary R Papenfuss; Martha Abrahamsen; Heather Stockwell; Dana E Rollison; Yougui Wu; Anna R Giuliano Journal: J Infect Dis Date: 2012-01-11 Impact factor: 5.226
Authors: Gabriella M Anic; Ji-Hyun Lee; Heather Stockwell; Dana E Rollison; Yougui Wu; Mary R Papenfuss; Luisa L Villa; Eduardo Lazcano-Ponce; Christine Gage; Roberto José C Silva; Maria L Baggio; Manuel Quiterio; Jorge Salmerón; Martha Abrahamsen; Anna R Giuliano Journal: J Infect Dis Date: 2011-10-19 Impact factor: 5.226
Authors: Donna J Ingles; Christine M Pierce Campbell; Jane A Messina; Mark H Stoler; Hui-Yi Lin; William J Fulp; Martha Abrahamsen; Bradley A Sirak; Michael T O'Keefe; Mary Papenfuss; Christine Gage; Roberto Carvalho da Silva; Rossana Gonzalez Sosa; Oscar Rojas Juarez; Luisa L Villa; Eduardo Lazcano Ponce; Anna R Giuliano Journal: J Infect Dis Date: 2014-10-24 Impact factor: 5.226
Authors: P Goggin; C Sauvageau; V Gilca; F Defay; G Lambert; S Mathieu-C; J Guenoun; E Comète; F Coutlée Journal: Hum Vaccin Immunother Date: 2017-12-13 Impact factor: 3.452
Authors: Gabriella M Anic; Jane L Messina; Mark H Stoler; Dana E Rollison; Heather Stockwell; Luisa L Villa; Eduardo Lazcano-Ponce; Christine Gage; Roberto Jose C Silva; Maria L Baggio; Jorge Salmerón; Anna R Giuliano Journal: J Med Virol Date: 2013-09 Impact factor: 2.327
Authors: Christine M Pierce Campbell; Jane L Messina; Mark H Stoler; Drazen M Jukic; Massimo Tommasino; Tarik Gheit; Dana E Rollison; Laura Sichero; Bradley A Sirak; Donna J Ingles; Martha Abrahamsen; Beibei Lu; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano Journal: J Clin Virol Date: 2013-10-16 Impact factor: 3.168
Authors: Mateja M Jelen; Zigui Chen; Boštjan J Kocjan; Felicity J Burt; Paul K S Chan; Diego Chouhy; Catharina E Combrinck; François Coutlée; Christine Estrade; Alex Ferenczy; Alison Fiander; Eduardo L Franco; Suzanne M Garland; Adriana A Giri; Joaquín Víctor González; Arndt Gröning; Kerstin Heidrich; Sam Hibbitts; Lea Hošnjak; Tommy N M Luk; Karina Marinic; Toshihiko Matsukura; Anna Neumann; Anja Oštrbenk; Maria Alejandra Picconi; Harriet Richardson; Martin Sagadin; Roland Sahli; Riaz Y Seedat; Katja Seme; Alberto Severini; Jessica L Sinchi; Jana Smahelova; Sepehr N Tabrizi; Ruth Tachezy; Sarah Tohme; Virgilijus Uloza; Astra Vitkauskiene; Yong Wee Wong; Snježana Zidovec Lepej; Robert D Burk; Mario Poljak Journal: J Virol Date: 2014-04-16 Impact factor: 5.103